



My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below), or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **BLOCKADE OF PROTEIN C ACTIVATION REDUCES**

BLOCKADE OF PROTEIN C ACTIVATION REDUCES MICROVASCULAR SURGICAL BLOOD LOSS

the specification of which (check one)

 X is attached hereto
_____ was filed on _____
_____ as application Serial No. _____
_____ and was amended on: _____
 (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Claimed
(Number)	(Country)	(Day/Month/Year Filed)	
(Number)	(Country)	(Day/Month/Year Filed)	
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	Status (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	Status (patented, pending, abandoned)

"Blockade of Protease Activation Reduces
Microvascular Surgical Blood Loss"

By: Philip C. Comp

Filed: July 24, 1992

DECLARATION

As named inventor, I hereby appoint the following attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

6

John S. Pratt	<u>29,476</u>
James L. Ewing, IV	<u>30,630</u>
Patrea L. Pabst	<u>31,284</u>
Jamie L. Greene	<u>32,467</u>
Cheryl K. Zalesky	<u>33,052</u>
Dean W. Russell	<u>33,452</u>

Send Correspondence to: Patrea L. Pabst, Esq.
Kilpatrick & Cody
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530

Direct telephone calls to: Patrea L. Pabst (404)815-6508, or
John S. Pratt (404)815-6367

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Philip C. Comp

Inventor's signature Philip C Comp Date 7-23-92

Residence 9805 Silver Lake Drive, Oklahoma City, Oklahoma 73162 OK

Citizenship United States

Post Office Address Same as above


Full name of second joint inventor (if any) _____

Inventor's signature _____ Date _____

Residence _____

Citizenship _____

Post Office Address _____



Applicant or Patentee: Philip C. Comp

Serial or Patent No.:

Attorney's

Filed or Issued: July 24, 1992

Docket No:

OMRF128

For:

BLOCKADE OF PROTEIN C ACTIVATION REDUCES
MICROVASCULAR SURGICAL BLOOD LOSS

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on
behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Oklahoma Medical Research
Foundation

ADDRESS OF ORGANIZATION: Oklahoma Medical Research
Foundation
825 N.E. 13th
Oklahoma City, Oklahoma 73104

TYPE OF ORGANIZATION

- ☐ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE
(26 USC 501(a) and 501(c)(3))

☒ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE
OF STATE OF THE UNITED STATES OF AMERICA

☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE
SERVICE CODE (26 USC 501(a) and 501(c)(3) IF LOCATED
IN THE UNITED STATES OF AMERICA

☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL
UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
IF LOCATED IN THE UNITED STATES OF AMERICA

(NAME OF STATE:)

(CITATION OF STATUTE:)

I hereby declare that the nonprofit organization identified
above qualifies as a nonprofit organization as defined in 37 CFR
1.9(e) for purposes of paying reduced fees under section 41(a)

"Blockade of Protein C Activation Reduces
Microvascular Surgical Blood Loss"

Filed: July 24, 1992

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS

and (b) of Title 35, United States Code with regard to the
invention entitled "Blockade of Protein C Activation Reduces Microvascular
Surgical Blood Loss" by Philip C. Comp
described in the specification filed July 24, 1992.

I hereby declare that rights under contract or law have been
conveyed to and remain with the nonprofit organization with
regard to the above-identified invention.

If the rights held by the nonprofit organization are not
exclusive, each individual, concern or organization having rights
to the invention is listed below* and no rights to the invention
are held by any person, other than the inventor, who could not
qualify as a small business concern under 37 CFR 1.9(d) or by any
concern which would not qualify as a small business concern under
37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named
person, concern or organization having rights to the invention
averring to their status as small entities. (37 CFR 1.27)

NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORG.

NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORG.

I acknowledge the duty to file, in this application or patent,
notification of any change in status resulting in loss of
entitlement to small entity status prior to paying, or at the
time of paying, the earliest of the issue fee or any maintenance

"Blockade of Protein C Activation Reduces
Microvascular Surgical Blood Loss"

Filed: July 24, 1992

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS

fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

William G. Thurman, M.D.

TITLE IN ORGANIZATION:

Oklahoma Medical Research Foundation

ADDRESS OF PERSON SIGNING:

825 N.E. 13th Street, Oklahoma City, OK 73104

William G. Thurman, M.D.

July 23, 1992

SIGNATURE

DATE